Robert Michel
Until Robert L. Michel came along and founded The Dark Intelligence Group (DIG) two decades ago, the clinical laboratory industry and the anatomic pathology profession lacked a trustworthy source for information about the management and operations of medical laboratories. From its inception in 1995, The Dark Report quickly became the “go to†source of industry intelligence, innovations in lab management, and strategic market analysis.
This excellence in reporting has earned recognition from his peers. For example, twice Michel and The Dark Report have won national awards for best investigative reporting by the Specialty Information Publishers Association. In 2005, the award was for Michel’s coverage about how the anatomic pathology condominium laboratories (pod labs) operated by urologists and gastroenterologists came to be, who operated them, and how these owners marketed the AP condo labs to other physician groups. In 2009, Michel’s award for best investigative reporting resulted from his published interviews with Quest Diagnostics Incorporated when the company admitted that, for a period of 18 months, it had been reported inaccurate Vitamin 25(OH) D results because of problems with its laboratory-developed test methodology. The Dark Report’s story was picked up by The New York Times and was in the national news cycle for several days.
In his role as Editor-in-Chief, Michel brought unique capabilities to DIG and The Dark Report. His management training and diverse business experience—along with his skills as a concise writer and analyst—proved to be a winning combination for readers of The Dark Report. For that reason, Michel’s story has many intriguing elements.
Immediately prior to founding DIG, he had served in several executive positions for Nichols Institute based in Portland, Oregon, and San Juan Capistrano, California. This was during the time that Nichols Institute was an independent public lab company with annual revenues of about $280 million (prior to its acquisition by MetPath, Inc., now Quest Diagnostics Incorporated). He traveled extensively to many of the clinical lab business units owned by Nichols Institute in different regions of the United States and played a role in formulating effective market strategies in response to the emergence of closed-panel HMOs, capitated pricing, and full-risk managed care contracts, among other successful management initiatives.
Prior to his service at Nichols Institute, Michel served at three different Fortune 100 companies. These were Procter & Gamble, Centex Corporation, and Financial Corp. of America. Each was an opportunity to master new management techniques and apply them in different industries. Between these positions, he gained experience as an entrepreneur, having founded a real estate development firm and a general contracting company in the Southeastern United States.
Robert Michel earned a Bachelor of Arts degree in Economics at the University of California, Los Angeles, where he played rugby, a sport he participated in for another 22 years. He is a native of California and grew up in Santa Ana.
Articles by Robert Michel
Lab Briefs: Roche, GenMark Diagnostics, Thermo Fisher, Mesa Biotech, ProPath
From the Volume XXVIII No. 5 – April 12, 2021 Issue
Roche to Acquire GenMark Diagnostics LAST MONTH, Roche and GenMark Diagnostics announced a definitive merger agreement for Roche to acquire GenMark in a transaction valued at $1.8 billion. …
Restitution and Guilty Plea in Two Lab Fraud Cases
From the Volume XXVIII No. 5 – April 12, 2021 Issue
CEO SUMMARY: In one case, owners and a sales rep agreed to pay restitution totaling almost $10 million. In the second case, three defendants pled guilty to federal charges involving payment or receipt of kickbacks and illegal inducements. A fourth defendent in this second case, a ph…
April 12, 2021 Intelligence: Late-Breaking Lab News
From the Volume XXVIII No. 5 – April 12, 2021 Issue
One clinical laboratory company now says it provides COVID-19 testing services to all five of the major men’s professional sports leagues in the United States. On April 1, BioReference Laboratories, Inc. (BRLI), a division of Opko Health, announced a new agreement with Major League…
Revised Stark Law, Anti-Kickback Statute Rules Are Good News for Labs
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
This is an excerpt of a 1,385-word article in the March 22, 2021 issue of  THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: The Dark Report explains how changes to the Stark Law and Anti-Kickback Statute will benefit labs,…
Revised Stark and AKS Rules Are Good News for Labs
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
CEO SUMMARY: It must be rewarding for federal rulemakers at the Centers for Medicare and Medicaid Services and the Office of the Inspector General to hear that attorneys representing clinical labs and pathology groups consider the new final rules for the Stark Law and the Anti-Kickb…
Understanding Key Parts of New AKS, Stark Law Rules
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
CEO SUMMARY: Both the federal Stark Law and Anti-Kickback Statute have been revised and the final rules became effective on Jan. 19. The good news for clinical laboratories and anatomic pathology groups is that federal regulators from the Centers for Medicare and Medicaid Services a…
Roche to Acquire GenMark, Ovation.io Raises $21.5M
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
Roche to Pay $1.8 Billion for GenMark THERE’S MORE CONSOLIDATION in the in vitro diagnostics (IVD) industry. It was announced on Mar. 15 that Roche Diagnostics would acquire GenMa…
What Comes Next? Predictions on COVID-19 Test Volumes in 2021-22
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
CEO SUMMARY: Incoming data show that the number of referrals for both COVID-19 tests and routine tests is in a decline that started in October and is continuing. This complicates the strategic planning for hospital/health system labs, independent labs, and pathology groups. They nee…
Truvian Sciences Raises $105M for Near-Patient Lab Test System
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
DESPITE THE PANDEMIC, investors continue to support emerging in vitro diagnostics (IVD) companies. This is particularly true of start-up companies that want to develop clinical lab testing systems that can be used at the point of care, that require small amounts of blood, and that deliver accu…
March 22, 2021 Intelligence: Late-Breaking Lab News
From the Volume XXVIII, No. 4 – March 22, 2021 Issue
This may be the nation’s first federal case of fraud and abuse involving a clinical laboratory company specializing in microbiome testing. In San Francisco last week, federal prosecutors filed multiple criminal charges against bankrupt uBiome, formerly based in San Francisco, Jessica Richman…
CURRENT ISSUE

Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized